+91-9561854529 editorinchief.ijama@gmail.com submitpaper@ijama.in Contact Form

Antimicrobial Resistance Surveillance in Hospital-Acquired Gram-Negative Infections

Author(s):Suresh Kumar Sharma, Anita Patel, Rajiv Mohan

Affiliation: Department of Clinical Microbiology and Infectious Diseases, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Page No: 55-61

Volume issue & Publishing Year: Volume 3, Issue 4, April 2026

published on: 2026/04/07

Journal: International Journal of Advanced Multidisciplinary Application.(IJAMA)

ISSN NO: 3048-9350

DOI: https://doi.org/10.5281/zenodo.19482934

Download PDF

Article Indexing:

Abstract:
Antimicrobial resistance (AMR) in hospital-acquired Gram-negative bacterial infections represents one of the most urgent threats to global health security, with carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase-producing organisms (ESBL), and multidrug-resistant Pseudomonas aeruginosa collectively accounting for an estimated 700,000 deaths annually from AMR-attributable infections. Indian tertiary care intensive care units represent epicentres of AMR selection pressure, combining critically ill immunocompromised patients, prolonged antibiotic exposures, device-associated infection risk, and the cross-transmission dynamics of high-density care environments. This study presents a four-year retrospective surveillance analysis (2020-2024) of antimicrobial resistance rates in Gram-negative hospital-acquired infections across twenty-two ICUs in eight major Indian cities, examining temporal trends in resistance to first-line, second-line, and last-resort antimicrobial agents. Microbiological data from 18,742 clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were extracted from participating institutions' laboratory information systems and linked to clinical outcome data including ICU length of stay, 30-day mortality, and antimicrobial treatment duration. Resistance rates across fourteen antimicrobial classes were calculated annually per organism. Results demonstrate a consistent temporal escalation in resistance across all three organisms and nearly all antimicrobial classes, with the most alarming trajectory observed for carbapenem resistance in K. pneumoniae (8.7% in 2020 to 18.3% in 2024) and meropenem resistance in E. coli (4.2% to 9.8%). Multivariable Cox regression identified carbapenem resistance as the strongest predictor of 30-day mortality (HR 3.42, 95% CI 2.87-4.07), confirming the clinical severity of the resistance escalation trend.

Keywords: antimicrobial resistance, carbapenem resistance, CRE, ESBL, Klebsiella pneumoniae, E. coli, ICU, hospital-acquired infections, AMR surveillance, Indian hospitals

Reference:

  • [1] Sharma, S. K., Patel, A., & Mohan, R. (2023). Four-year trends in carbapenem resistance in Indian tertiary care ICUs: Implications for empirical therapy protocols. Indian Journal of Medical Microbiology, 41(3), 718-729.
  • [2] Cassini, A., Hogberg, L. D., Plachouras, D., et al. (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU. Lancet Infectious Diseases, 19(1), 56-66.
  • [3] ICMR. (2023). Antimicrobial Resistance Research and Surveillance Network (AMRSN) Annual Report 2022. Indian Council of Medical Research, New Delhi.
  • [4] GBD 2019 AMR Collaborators. (2022). Global mortality associated with 33 bacterial pathogens in 2019. Lancet, 400(10369), 2221-2248.
  • [5] Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011). Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clinical Infectious Diseases, 53(1), 60-67.
  • [6] Mohan, R., Sharma, S. K., & Patel, A. (2022). NDM-1 Klebsiella pneumoniae nosocomial transmission in Indian tertiary hospital ICUs: Genomic epidemiology analysis. Journal of Antimicrobial Chemotherapy, 77(6), 1618-1626.
  • [7] Patel, A., Mohan, R., & Sharma, S. K. (2023). Clinical outcomes of carbapenem-resistant Gram-negative infections in Indian ICUs: A four-year retrospective cohort. Indian Journal of Critical Care Medicine, 27(4), 248-258.
  • [8] Magiorakos, A. P., Srinivasan, A., Carey, R. B., et al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria. Clinical Microbiology and Infection, 18(3), 268-281.
  • [9] Murray, C. J., Ikuta, K. S., Sharara, F., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019. Lancet, 399(10325), 629-655.
  • [10] Ministry of Health and Family Welfare. (2017). National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017-2021. Government of India, New Delhi.
  • [11] Kumar, S. G., Adithan, C., Harish, B. N., et al. (2013). Antimicrobial resistance in India: A review. Journal of Natural Science, Biology and Medicine, 4(2), 286-291.
  • [12] Sharma, S. K., Mehta, Y., & Gupta, A. (2021). Antimicrobial stewardship in Indian ICUs: National audit findings and implementation barriers. Indian Journal of Pharmacology, 53(4), 298-307.
  • [13] WHO. (2019). Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis. World Health Organization, Geneva.
  • [14] WHO. (2022). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. World Health Organization, Geneva.
  • [15] Laxminarayan, R., Duse, A., Wattal, C., et al. (2013). Antibiotic resistance — the need for global solutions. Lancet, 382(9893), 1057-1098.